Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.
Centre de Résonance Magnétique Biologique et Médicale, Unité Mixte de Recherche 6612 Centre National de Recherche Scientifique, Faculté de Médecine de Marseille, Université de Méditerranée (Aix-Marseille II), Marseille, France.
Slim
S
Fellah
Nadine
N
Girard
Olivier
O
Chinot
Patrick J
PJ
Cozzone
Virginie
V
Callot
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D017809:Fatal Outcome; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077146:Irinotecan; D018810:Magnetic Resonance Angiography; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D013113:Spin Labels
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D013113:Spin Labels; D000068258:Bevacizumab; D000077146:Irinotecan; D002166:Camptothecin